Health & Education · Warsaw

Obesity drug makers lobby for reimbursement that could cost Poland 1.4-1.5 bn zloty

Eli Lilly and Novo Nordisk paid about 25 million zloty to doctors and health groups in 2025, while Poles spent almost 1.5 billion zloty on Mounjaro and Wegovy out of their own pockets.

AI text based on reports by rmf24.pl and Rzeczpospolita. Published . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

Warsaw · Poland

Payments to the medical sector

Eli Lilly and Novo Nordisk, which make the obesity drugs Mounjaro and Wegovy, paid doctors and health organisations about 25 million zloty in 2025. Of that sum, 16 million zloty went to sponsorship of scientific societies, universities, hospitals and patient organisations, and 9 million zloty covered fees for medical services. These figures leave out extra costs such as funding doctors' trips to conferences. The payments form part of a wider pattern in which manufacturers finance the people and groups that shape treatment debates.

Payments by Eli Lilly and Novo Nordisk, 2025mln zł
Sponsorship of societies, universities, hospitals and patient groups
16 mln zł
Fees for medical services
9 mln zł

Data from the article text

Campaigns and lobbying

Campaigns and educational initiatives on treating obesity are partly financed by the manufacturers. Some of the organisations taking part in events, including ones held in parliament, are financed by the drugmakers. Monika Wielichowska, deputy Marshal of the Sejm, and senator Agnieszka Gorgoń-Komor, both from the Civic Coalition, are named as especially active in the fight against obesity. Representatives of the Ministry of Health have voiced concern that lobbying has gone beyond the walls of parliament and the limits of decency.

Reimbursement and the state budget

Applications for reimbursing the two drugs are on the table, but the president of the Agency for Health Technology Assessment and Tariff System (AOTMiT) has not yet recommended reimbursing either therapy. Estimates put the extra cost to the budget at about 550 million zloty over two years for Mounjaro and about 860 million zloty over four years for Wegovy. Rzeczpospolita puts the total cost to the state at 1.4 billion zloty over several years, while another article gives about 1.5 billion zloty over several years. The gap between the two figures is one of the open questions in the debate.

Estimated extra reimbursement cost to the statemln zł
Mounjaro (2 years)
550 mln zł
Wegovy (4 years)
860 mln zł

Data from the article text

What patients pay now

Polish patients already spent heavily on these products in 2025 out of their own pockets. They paid 1.292 billion zloty for Mounjaro and 182 million zloty for Wegovy, almost 1.5 billion zloty in total. According to Rzeczpospolita, adding Ozempic and Rybelsus, which are used outside their approved indications, pushes the figure above 2 billion zloty. The two obesity drugs rank among the top-selling non-reimbursed prescription medicines in Poland by revenue. The data come from the latest report of the Economic Commission at the Ministry of Health.

Spending on Mounjaro and Wegovy by Poles, 2025mln zł
Mounjaro
1292 mln zł
Wegovy
182 mln zł

Data from the article text

Who benefits

Besides the manufacturers, doctors, health experts and patient organisation representatives benefit from the treatment market. Their names and affiliations appear in transparency reports that the drugmakers publish. Rzeczpospolita describes the market for obesity drugs as worth at least 1.5 billion zloty a year. The Foundation for Obesity Treatment (FLO), set up in 2023, is among the main actors in the debate.

Ask about this text

Sources and context

Places
Warsaw

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar